Stop the TPP from Putting HIV Treatment Out of Reach!
October 20, 2015
TPP stands for Trans-Pacific Partnership. It is a giant free trade agreement that is being negotiated by 12 countries that border on the Pacific Ocean, including the U.S.
The TPP will make it easier for pharmaceutical companies to demand longer patent extensions. By extending their patents, corporations can keep cheaper generic drugs from coming onto the market. Currently, competition between generic and "name-brand" drugs can bring the price of a drug down by anywhere from 30% to 80% of their original cost. About 90% of the drugs taken to treat HIV globally are affordable, generic medicines.
Where Are We Now?
TPP is the first of three major international treaties being negotiated by trade representatives from various countries. The other two are the Transatlantic Trade and Investment Partnership (TTIP, with European partners) and the Trade in Services Agreement (TiSA, with 50 other countries). The U.S. is a negotiating partner in all three of these.
Each of these treaties is being negotiated secretly. Even our Congress members have not been allowed to see the treaty drafts, which are written by Administration officials and hundreds of "advisors" working for multinational corporations. TPP negotiations started in 2010 and ended on October 5, 2015. The treaty chapter covering drug pricing is now online, thanks to Wikileaks.
Last June, Congress gave President Obama "fast track authority" to move the TPP and other such bills through Congress without any debate. In doing so, they surrendered our right, as citizens and tax-payers, to hear and participate in public debate on this issue. This makes it all the more important that we hold them accountable for how they vote on the TPP. In the next few months, Congress will receive the TPP full text and have 60 days to consider it before voting "yes" or "no". We must urge our legislators now to vote NO on TPP.
What Are We Up Against?
Passing TPP will ensure that even fewer people living with HIV will have uninterrupted access to the antiretroviral (ARV) drugs they need to stay alive. About 37 million people are now living with HIV. About 15 million of them have access to ARVs. Without these drugs (usually generics) people with HIV develop AIDS and die. There is no alternative.
Through PEPFAR, the U.S. government is dedicating over $5.2 billion tax dollars in FY2016 to the goal of ending AIDS. What sense does it make to invest so much in that goal while simultaneously passing the TPP and allowing pharmaceutical corporations to force affordable, generic ARVs off the market both here in the U.S. and abroad?
TPP passage will also raise ARV prices and decrease generic drug access in the U.S. The AIDS Drug Assistance Program (ADAP) and private insurance plans will be stretched even further and the adequacy of their coverage will go down as drugs prices rise and generics become scarce.
So How Do We Get Them to Vote No?
This article was provided by HIV Prevention Justice Alliance. Visit HIV Prevention Justice Alliance's website to find out more about their activities and publications.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)